Document is current
Any future updates will be listed below
-
Authors
Guccione, Caitlin
Patel, Lucas
Tomofuji, Yoshihiko
McDonald, Daniel
Gonzalez, Antonio
Sepich-Poore, Gregory D. https://orcid.org/0000-0002-3443-3715
Sonehara, Kyuto https://orcid.org/0000-0002-4536-1761
Zakeri, Mohsen
Chen, Yang
Dilmore, Amanda Hazel
Damle, Neil
Baranzini, Sergio E. https://orcid.org/0000-0003-0067-194X
Hightower, George
Nakatsuji, Teruaki https://orcid.org/0000-0002-6187-2991
Gallo, Richard L. https://orcid.org/0000-0002-1401-7861
Langmead, Ben https://orcid.org/0000-0003-2437-1976
Okada, Yukinori https://orcid.org/0000-0002-0311-8472
Curtius, Kit https://orcid.org/0000-0002-2678-0960
Knight, Rob
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA023100, NIH/NIGMS T32GM007198, NIH Pioneer DP1AT010885)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI U24CA248454)
U.S. Department of Health & Human Services | Centers for Disease Control and Prevention (CDC award 75D301-22-C-14717)
AGA Research Foundation (AGA Research Scholar Award AGA2022-13-05)
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 7 January 2025
First Online: 18 January 2025
Competing interests
: D.M. is a consultant for BiomeSense, Inc., has equity and receives income. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. G.H. is the recipient of the Robert A. Winn Diversity in Clinical Trials: Career Development Award, which is partly funded by Bristol-Meyer Squibb Foundation. B.L. is the owner of InOrder Labs LLC. K.C. has research grant support from Phathom Pharmaceuticals. R.K. is a scientific advisory board member, and consultant for BiomeSense, Inc., has equity and receives income. He is a scientific advisory board member and has equity in GenCirq. He is a consultant for DayTwo, and receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder of Biota, Inc., and has equity. He is a cofounder of Micronoma, and has equity and is a scientific advisory board member. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The remaining authors declare no competing interests.
